Iceni™ Pharmaceuticals benefits from an expert advisory board with broad clinical and commercial expertise in multiple myeloma, bone disease and cilengitide.
Annalisa Jenkin’s previous roles include Head of Global Research & Development at Merck Serono, during which time cilengitide was one of the drug development programs. Prior to this, she held several leadership roles at Bristol Myers-Squibb (BMS) from 1997 to 2011, most recently serving as Senior VP and Head of Global Medical Affairs. Click for Bio
Dr Osterwalder is a board certified hematologist and oncologist with a background of 15 years of academic and clinical practice in internal medicine, hematology and oncology (Swiss Board Certifications). This was followed by 24 years in global drug development and strategic portfolio management in the fields of oncology and immune-oncology drug development at F. Hoffmann-La Roche (VP Clinical development (anemia)) and Merck Serono (Senior VP & Senior Strategic Adviser (Oncology)). Click for Bio
Dr Kearsey has over sixteen years’ experience in drug development in the biotech sector in several life sciences companies ExonHit (France), Diatos (France), and Beta cell NV (Belgium). He is a co-founder & Director at Leads To Development, a Paris based company providing expertise in the development of therapeutic molecules. Click for Bio